New Retina Radio
New Retina Radio

02.22.24

The State of Biosimilars: How We Got Here and What It Means for Practice

Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care?  Moderator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices.  This podcast is editorially independent, supported with advertising by Sandoz. 

View full description +

MORE EPISODES

08.12.26

The Fellow Eye: Episode 6

Justin C. Muste, MD; David Fell, MD; Monia Reding, MD; and Benjamin Young, MD

08.05.26

ASRS '26: SOL-1 and TRUCKEE at 4.5 Years

Dilsher Dhoot, MD; and Carl Danzig, MD

07.16.26

New Retina Radio Journal Club w/ VBS: Clinical Features and Outcomes of IOFB Removal

Jordan Deaner, MD; Vaidehi Dedania, MD; and Rehan Hussain, MD

07.08.26

Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.08.26

Evolving Practice Patterns and Dosing Strategies in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.08.26

Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

07.01.26

The Fellow Eye: Episode 5

Justin C. Muste, MD; David Fell, MD; Omesh P. Gupta, MD; and Shane Griffin, MD, MCR

06.26.26

Retinal Perfusion, Sensitivity, and Function in DR

Barton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD

Show More